Marien Hospital Herne Universitätsklinikum der Ruhr-Universität Bochum
- Address
- Hoelkeskampring 40, 44625 Herne, Germany
Marien Hospital Herne Universitätsklinikum der Ruhr-Universität Bochum
Marien Hospital Herne, a university hospital affiliated with Ruhr-Universität Bochum, demonstrates specialized expertise in urological oncology with a particular focus on bladder cancer research and treatment innovations. The center is actively engaged in advancing therapeutic strategies across the spectrum of bladder cancer presentations, from early-stage localized disease to advanced muscle-invasive malignancies.
- Perioperative immunotherapy and targeted therapy combinations for muscle-invasive bladder cancer
- Novel intravesical drug delivery systems for localized bladder cancer treatment
- Comparative effectiveness studies of chemotherapy versus immunotherapy regimens
The institution's research portfolio includes pivotal Phase 3 trials evaluating perioperative enfortumab vedotin with pembrolizumab compared to standard neoadjuvant chemotherapy in cisplatin-eligible patients undergoing radical cystectomy. Additionally, the center investigates innovative approaches such as erdafitinib intravesical delivery systems, reflecting their commitment to both systemic and localized therapeutic strategies for non-muscle-invasive and muscle-invasive bladder cancer populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 90 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 76 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1AstraZeneca AB1active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Marien Hospital Herne Universitätsklinikum der Ruhr-Universität Bochum
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 90 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adezunap | 4 | Unknown | 2023-11-02 | 2023-11-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.